Relapsed/Refractory Small Cell Lung Cancer
Conditions
Keywords
Small Cell Lung Cancer, SCLC, AMG 757, Tarlatamab, IMDELLTRA^TM
Brief summary
The main aim of this study is to: * evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by investigator) of 2 dose levels of tarlatamab for Part 1 only * evaluate anti-tumor activity of tarlatamab as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2 * evaluate safety of reduced mandatory monitoring period in Cycle 1 at selected dose of tarlatamab for Part 3
Interventions
DRUGTarlatamab
Intravenous (IV) infusion
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant has provided informed consent/assent prior to initiation of any study specific activities/procedures. * Male and female participants ≥ 18 years of age (or legal adult age within country) at the time of signing the informed consent. * Histologically or cytologically confirmed relapsed/refractory SCLC * Participants who progressed or recurred following 1 platinum-based regimen and at least 1 other prior line of therapy. * Participants willing to provide archived tumor tissue samples or willing to undergo pretreatment tumor biopsy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 1. * Minimum life expectancy of 12 weeks. * Measurable lesions as defined per RECIST 1.1 within 21 days prior to the first dose of tarlatamab. * Participants with treated brain metastases are eligible provided they meet defined criteria.
Exclusion criteria
Disease Related * Untreated or symptomatic brain metastases and leptomeningeal disease. * Has evidence of interstitial lung disease or active, non-infectious pneumonitis. * Participants who experienced recurrent pneumonitis (grade 2 or higher) or severe, life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents. * Unresolved toxicity from prior anti-tumor therapy, defined as per protocol. Other Medical Conditions * History of other malignancy within the past 2 years, with exceptions * Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 12 months of first dose of tarlatamab. * History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months of first dose of tarlatamab. * Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of tarlatamab. * Presence of any indwelling line or drain. * History of hypophysitis or pituitary dysfunction. * Exclusion of hepatitis infection based on the results and/or criteria per protocol. * Major surgery within 28 days of first dose of tarlatamab. * History or evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Subject is eligible if no acute symptoms of coronavirus disease 2019 (COVID-19) within 14 days prior to first dose of tarlatamab (counted from day of positive test for asymptomatic subjects). Prior/Concomitant Therapy * Participant received prior therapy with tarlatamab. * Prior anti-cancer therapy within 28 days prior to first dose of tarlatamab. * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of tarlatamab. * The following vaccines (live and live-attenuated vaccines) are excluded during the following study periods: 1. Screening and during study treatment: Live and live-attenuated vaccines are prohibited within 28 days prior to the first dose of tarlatamab and for the duration of the study. Live viral non-replicating vaccine (e.g. Jynneos) for Monkeypox infection is allowed during the study (except during cycle 1) in accordance with local standard of care and institutional guidelines. 2. End of study treatment: Live and live-attenuated vaccines can be used when at least 42 days (5X half-life of tarlatamab) have passed after the last dose of tarlatamab. Other Exclusions * Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of tarlatamab. * Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of tarlatamab. * Female participants planning to become pregnant while on study through 60 days after the last dose of tarlatamab. * Female participants of childbearing potential with a positive pregnancy test assessed at screening and/or day 1 by a highly sensitive urine or serum pregnancy test. * Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of tarlatamab. * Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of tarlatamab. * Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of tarlatamab. * Participant has known sensitivity to any of the products or components to be administered during dosing. * Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures. * History or evidence of any other clinically significant disorder, condition or disease determined by the investigator or Amgen physician. Specific Exclusions to Part 3 * Participants unable to remain within one hour of study site for 48 hours after infusion of tarlatamab on Cycle 1 Day 1 and Cycle 1 Day 8. * Participants unable to remain within one hour of any hospital for 72 hours after infusion of tarlatamab on Cycle 1 Day 1 and Cycle 1 Day 8. * Unable to identify home companion who will cohabitate with participant for 72 hours after infusion of tarlatamab on Cycle 1 Day 1 and Cycle 1 Day 8.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 61 months |
| Part 1 and Part 3 Only: Number of Participants who Experience One or More Treatment-emergent Adverse Events | Up to a maximum of 61 months |
| Part 1 Only: Serum Concentrations of Tarlatamab | Up to a maximum of 24 months |
| Part 1 and Part 2 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 61 months |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 73 months |
| Disease Control (DC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 73 months |
| Duration of Disease Control (DC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 73 months |
| Progression-free Survival (PFS) Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 73 months |
| Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months |
| Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months |
| Disease Control (DC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months |
| Duration of Disease Control (DC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months |
| Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months |
| Overall Survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months |
| Number of Participants who Experience One or More Treatment-emergent Adverse Events | Up to a maximum of 73 months |
| Serum Concentrations of Tarlatamab | Up to a maximum of 24 months |
| Number of Participants who Experience Anti-Tarlatamab Antibody Formation | Up to a maximum of 73 months |
Countries
Austria, Belgium, Denmark, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Portugal, Singapore, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States
Contacts
STUDY_DIRECTORMD
Amgen
Outcome results
None listed